用Rituximab治疗的获得的V因子抑制剂
Faisal Ansari1, Yurhee Lee2, Umar Ansari3
1Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, Michigan, USA faisal.ansari@wmed.edu.
BMJ case reports
|November 18, 2024
概括
获得的V因子抑制剂很少见,难以诊断. 利图西马布作为V因子抑制剂患者的有效治疗选择具有前景,提供了潜在的新疗法.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 获得的V因子 (FV) 抑制剂是罕见的自身免疫疾病.
- 由于不同的临床表现和缺乏标准治疗,诊断具有挑战性.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.7K
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
3.5K
相关概念视频
01:21Rheumatic Heart Disease III: Medical Management
3
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
3
01:14Myocarditis III: Medical Management
2
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
2